Nasdaq · Biotech stocks database
UNCY (Unicycive Therapeutics Inc.) stock: $3.55, $98.9M market cap, $41.3M cash, $57.6M EV, $162.0M fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We are a clinical-stage biotechnology company focused on identifying, developing, and commercializing innovative therapies to address significant unmet medical needs, with an initial focus on kidney disease. Founded in 2016, Unicycive was established to create a streamlined and efficient drug development platform capable of accelerating the advancement of promising therapies from discovery to commercialization.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $41.3M |
|---|---|
| Debt | $0.0M |
| Net cash | $41.3M |
| Enterprise value | $57.6M |
| Basic shares | 27.9M shares |
| Fully diluted shares | 45.6M shares |
| Fully diluted market cap | $162.0M |
| Cash per share | $1.48 |
| Quarterly burn | $7.6M |
| Cash runway | 5.4 quarters |
Cash figures as of 2026-06-30. Database snapshot: 2026-11-07.
Cap table as of 2026-06-30.
Loading UNCY daily closes…